4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001209191-23-059908
President and CEO sold 12,000 shares at $14.64 ($175,709)
- President and CEO acquired 12,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kintz Samuel · President and CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-12-26 | Exercise or conversion : show line 1 in the form 10b5-1 | +12,000 | $1.12 | $13,440 | 12,000 | D |
| 2023-12-26 | Sale : show line 2 in the form 10b5-1 | −12,000 | $14.64 | $175,709 | 0 | D |
| Open-market sales · 12,000 sh · avg $14.64 · $175,709 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-12-26 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −12,000 | 296,550 | D |
Loading xslF345X05/doc4.xml…